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Introduction
AST-120, also known as kremezin, is an orally 
administered intestinal sorbent which has been 
reported to slow chronic kidney disease (CKD) 
progression and delay the initiation of dialysis by 
reducing the levels of renal toxins or their precur-
sors in the gastrointestinal (GI) tract [Konishi 
et al. 2008]. AST-120 takes the form of spherical 
particles, 0.2–0.4 mm in diameter, composed 
predominantly of porous carbon material with a 
high surface area, exceeding over 1600 m2/g 
[Marier et al. 2006]. The abundant porosity and 
its wide distribution provide an extensive and effi-
cient binding surface, which enables selective 
adsorption and removal of low molecular weight 
substances from the intestinal lumen. Noteworthy, 
the unique composition of AST-120 particles and 
inaptitude to dissolve in water and organic sol-
vents provide lower adsorption capability for 
amylase, pepsin, lipase, and chymotrypsin in 
comparison with activated charcoal [Marier et al. 
2006; Schulman et al. 2014].
AST-120 has been used as a renoprotective agent 
in Japan since 1991; it has also been made availa-
ble in Korea (since 2005) and the Philippines 
(since 2010). Its therapeutic indication is to pro-
long the time to initiation of dialysis therapy and 
to improve uremic symptoms in patients with 
CKD stage 4–5 [Schulman et al. 2014]. Moreover, 
studies confirm a positive role of AST-120 in pre-
venting cell senescence and vascular calcification, 
and consequently delaying progression of cardio-
vascular diseases (CVDs). More recently, the pos-
sibility of using AST-120 in the treatment of 
several other diseases, such as irritable bowel syn-
drome (IBS), has been suggested. IBS is a chronic, 
relapsing functional bowel disorder, associated 
with altered GI motility, secretion and sensitivity. 
It is the most commonly diagnosed GI condition 
in the population worldwide, which considerably 
reduces patients’ quality of life. Although a fair 
number of pharmacological targets have been pro-
posed for alleviating IBS symptoms, only a small 
number of therapeutics have been implemented, 
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implying that there is still need for a more plausi-
ble way of IBS prevention and treatment. Here, we 
discuss both advantages and disadvantages of 
AST-120 as a potential anti-IBS drug.
Molecular mechanisms of action of AST-120
One of the mechanisms by which AST-120 exhib-
its its favourable effects in CKD is by decreasing 
the levels of nephrotoxic metabolites in serum, 
including advanced glycation end products 
(AGEs), indoxyl sulfate (IS) and p-cresol. Both IS 
and p-cresol are protein-bound uremic toxins that 
originate from protein fermentation by intestinal 
bacteria. Dietary tryptophan is metabolized to 
indole, absorbed into the peripheral blood and 
further converted to IS in the liver. In compari-
son, p-cresol emanates from the catabolism of the 
amino acids tyrosine and phenylalanine, and if 
synthesized by bacteria, undergoes conjugation 
via sulfotransferases in the submucosal tissue of 
the gut [Bohlender et al. 2005; Dou et al. 2004]. 
Therefore, in the plasma p-cresol occurs notably 
in the form of p-cresyl sulfate (PCS) [Watanabe 
et al. 2013]. The excretion of IS and other uremic 
toxins is of limited efficacy in patients with renal 
dysfunction. Consequently, accumulation of ure-
mic toxins impairs renal function and leads to 
further buildup of circulating toxins, which in 
turn intensifies the state of disease and enhances 
renal failure and mortality of patients with CKD. 
Several studies confirmed that AST-120 can ham-
per this vicious circle by adsorbing uremic toxins 
in the intestines, what stimulates their excretion 
into faeces and consequently retard the functional 
and histological aggravation in patients with CKD 
and animal models [Shoji et al. 2007; Maeda et al. 
2009; Miyazaki et al. 2000].
Intracellular accumulation of IS through organic 
anion transporters (OAT1 and OAT3) and 
enhanced production of reactive oxygen species 
(ROS) by nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, particularly Nox4, 
result in greater toxicity of IS and thus mediate 
further progression of CKD [Ito et al. 2010; 
Motojima et al. 2003]. Several studies reported a 
positive linear correlation between IS and oxida-
tive biomarker levels, acrolein and 8-hydroxyl-2′-
deoxyguanosine, which accelerate progression of 
uraemia [Nakagawa et al. 2006; Fujii et al. 2009]. 
However, one needs to mention that recent litera-
ture suggests antioxidant activity of IS against 
hydroxyl radicals under physiological conditions 
[Miyamoto et al. 2010].
In parallel with renal damage progression, ele-
vated accumulation of toxins in circulating blood 
may also contribute to vascular alterations, 
including atherosclerotic lesions, which enhance 
the probability for cardiovascular event occur-
rence. A number of studies have indicated that IS 
induces endothelial dysfunction and plays a dom-
inant role in monocyte adhesion during inflam-
mation by releasing endothelial microparticles, 
such as tumour necrosis factor (TNF)-α and 
interleukin 1β [Ito et al. 2010]. In vitro, uremic 
toxins reduce the endothelial response to inflam-
matory cytokines, increase vascular permeability 
and promote elastolytic metalloproteinase release. 
Moreover, some clinical relevance has also been 
attributed to the action of PCS, which causes 
upregulation of the inflammatory cytokines, such 
as transforming growth factor (TGF)-β, tissue 
inhibitor of metalloproteinase-1 (TIMP-1), and 
pro-α1 collagen in the human kidney-2 (HK-2) 
cell line [Watanabe et al. 2013]. In addition, 
PCS displays pro-oxidant properties through 
activation of NADPH oxidase and increase in 
TGF-β1 and ROS production, which result in 
augmentation of cytoskeleton changes in vascular 
endothelial cells [Watanabe et al. 2013; Martin-
Garrido et al. 2011]. Furthermore, Dou and col-
leagues speculated that p-cresol has an inhibitory 
effect on endothelial proliferation and exhibits 
self-healing ability, and therefore can be associ-
ated with the effects on the endothelial actin 
cytoskeleton [Dou et al. 2004]. Eventually, the 
accumulation of PCS alters endothelial function 
and is attributable to enhanced mortality rate 
among patients on haemodialysis [Meijers et al. 
2009; Schepers et al. 2007].
Recent reports suggest that AST-120 signifi-
cantly reduced gene expression of TGF-β1, 
TIMP-1 and pro-α1 (I) collagen in the renal 
cortex of uremic rats [Miyazaki et al. 2000; 
Inami et al. 2014]. Furthermore, Nakagawa and 
colleagues [Nakagawa et al. 2006] reported that 
AST-120 decreased serum creatinine and uri-
nary protein levels, and attenuated histological 
changes, such as glomerular sclerosis and 
interstitial fibrosis [Lee et al. 2010]. Reduction 
in serum IL-6, serum creatinine (sCr), esti-
mated glomerular filtration rate and suppressed 
urinary excretion levels of 8-OHdG and L-fatty 
acid binding protein, markers of oxidative stress 
and tubular injury, have also been connected 
with the administration of AST-120 to patients 
with uraemia [Nakagawa et al. 2006; Nakamura 
et al. 2011].
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AST-120 alleviates progression of CKD
The usefulness of AST-120 in the treatment of 
CKD is supported by retrospective studies, 
including those conducted by Ueda and col-
leagues [Ueda et al. 2008] and Inami and col-
leagues [Inami et al 2014]. Similarly, long-term 
effects of AST-120 in patients with chronic renal 
failure in the predialysis stage were also reported 
[Maeda et al. 2009]. In contrast, some recent 
randomized control trials revealed no significant 
evidence in the effectiveness of the orally admin-
istered AST-120 in preventing or delaying the 
progression of CKD after 1 year of treatment 
[Akizawa et al. 2009; Wu et al. 2014]. However, it 
has to be mentioned that no serious adverse 
events were identified. Recently, large phase III 
clinical trials on 2000 subjects have been initi-
ated in North/Latin America and Europe; the 
data are still being analyzed [Schulman et al. 
2014].
AST-120 in CVDs
CVDs are a hallmark of patients with uraemia. 
It has been reported that the probability of car-
diac mortality in patients receiving dialysis is 
10–20 fold higher in comparison to those with-
out CKD [Johnson et al. 2007]. Moreover, a 
relation between CVD and renal failure was 
found even in patients with minor renal dys-
function [Go et al. 2004]. Many studies proved 
that IS is a key factor, which triggers injury to 
endothelial and vascular smooth muscle cells in 
patients with CVD, mainly because of aortic 
calcification and wall thickening [Adijianfg et al. 
2008]. Moreover, certain proinflammatory 
cytokines, AGEs and monocytes/macrophages, 
which are present in the calcified vascular wall, 
may favour vascular or valvular calcifications 
[Massy et al. 2005 ].
Studies have shown that AST-120 can be effective 
in delaying the progression of arteriosclerosis, 
wall thickening and consequently improve CVD 
[Muteliefu et al. 2012; Nakai et al. 2011; 
Shibahara and Shibahara, 2010]. Interestingly, a 
study by Adijiang and Niwa demonstrated that 
administration of AST-120 preserves renal expres-
sion of Klotho and prevents tubular cell senes-
cence in the kidneys of chronic renal failure (CRF) 
rats [Adijiang and Niwa, 2010]. A decreased 
expression of Klotho, a protein predominantly 
expressed in mouse, rat and human kidneys, may 
play an important role in vascular calcification, 
arteriosclerosis and osteoporosis development.
AST-120 in IBS
A fair number of factors, such as colonic motor 
disturbances, visceral hypersensitivity or augmen-
tation in mucosal permeability impair the func-
tion of the intestines and may lead to IBS 
development. AST-120 has affinity for several 
molecules implicated in the etiopathology of IBS, 
including neuroactive agents (serotonin, hista-
mine, tyramine, tryptamine and caffeine), toll-like 
receptor ligands, bacterial exotoxins (Escherichia 
coli heat stable enterotoxin, Shigella dysenteriae 
type 1 Shiga toxin, and Vibrio cholera cholera 
toxin) and bile acids (BAs), and could thus be 
regarded as a potential anti-IBS drug [Araki et al. 
2000; Soares, 2014; Furuhashi and Hotamisligil, 
2008]. Noteworthy, a nonmetabolized AST-120 
displays minimal, if any, interference with diges-
tive enzymes and exerts no significant effect on 
the adsorption of fat-soluble vitamins, allowing 
patients with IBS to maintain a nutritional diet 
during the long-term therapy [Schulman et al. 
2014; Soares, 2014; Tack et al. 2011].
AST-120 and its role in intestinal permeability 
and epithelial barrier
It has been suggested that low-grade mucosal 
inflammation underlies the development of IBS, 
and mucosal mast cells (MCs) are thought to play 
a particular role in the process. MCs, which can 
be found throughout the GI tract, including the 
duodenum, ileum, jejunum, caecum, colon and 
rectum, are implicated in the pathophysiology of 
IBS due to their ability to regulate intestinal per-
meability and the integrity of the epithelial barrier 
[Vivinus-Nebot et al. 2012; Park et al. 2006]. The 
correlation between MCs’ presence and the sever-
ity of abdominal pain, bloating and altered bowel 
habit, which are common features in patients with 
IBS, were confirmed in several studies [Park et al. 
2006; Barbara et al. 2004]. In accordance, 
O’Sullivan reported an increase in MCs in the 
caecal mucosa of patients with IBS compared 
with normal controls [O’Sullivan et al. 2000].
Degranulation of MCs contributes to mucosal 
inflammation by releasing potent inflammatory 
and immune modulators. Of all, tryptase has 
recently attracted most attention as it may release 
protease-activated receptor 2 (PAR-2) located at 
the basolateral site of enterocytes, which affects 
paracellular permeability and alters gut motility 
and thus generates IBS symptoms (Lee et al. 2010). 
PAR-2 causes a rearrangement in the cytoskeletal 
organization of tight junction proteins, which allows 
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passage of macromolecules and bacteria across 
the intestinal epithelial barrier resulting in inten-
sified inflammation and infection [Eutamene 
et al. 2003]. It has not been examined yet whether 
AST-120 has any affinity to tryptase and whether 
it can suppress an enhanced mucosal permeabil-
ity. However, it can easily be hypothesized that the 
coadministration of AST-120 and tryptase inhibi-
tors may further diminish intestinal mucosal per-
meability and downregulate the immune-mediator 
response.
AST-120 and intestinal hypersensitivity
Animal studies showed that an increased level of 
mediators released upon MC activation may alter 
the enteric nervous system (ENS) activity and is 
prone to increase visceral sensitivity [Eutamene 
et al. 2003]. Due to close proximity to mucosal 
innervations, MC-derived mediators provide neu-
roimmune interaction, provoke hyperexcitability 
of nociceptive visceral sensory nerves, and disturb 
smooth muscle function [Matricon et al. 2012]. 
The major chemical mediators derived from MCs 
are histamine, serotonin (5-HT), platelet-activat-
ing factor, tryptase, chymase, prostaglandins, 
cytokines and leukotrienes [Matricon et al. 2012]. 
It is important to note that an increased level 
of MCs is observed in a subgroup of patients 
with IBS [Barbara et al. 2004]; it can thus be sug-
gested that the capability of AST-120 to adsorb 
MC-derived mediators would prevent sensitiza-
tion of nociceptors in the intestinal mucosa and 
therefore reduce abdominal pain and discomfort 
common among patients with IBS.
There is a large body of evidence for a decreased 
activity of the rectal serotonin reuptake trans-
porter (SERT) in patients with IBS [El-Salhy 
et al. 2013]. An impaired SERT function leads to 
an extensive increase in the number of 5-HT mol-
ecules within the gut mucosa, which simultane-
ously influence ENS and the central nervous 
system (CNS), impact lymphocyte proliferation, 
promote T-cell recruitment and inhibit immune 
cell apoptosis [Khan and Ghia, 2010]. An 
increased availability of 5-HT modulates the 
afferent mechanohypersensitivity and accelerates 
segmental contractile colonic motor activity via 
the H1 and H2 receptors [Barbara et al. 2004]. 
Studies revealed that an elevated level of 5-HT is 
observed in diarrhoea-predominant IBS (IBS-D), 
and concurrently its decrease is associated with 
constipation-predominant IBS (IBS-C). Taken 
together, the administration of AST-120 may 
prolong intestinal passage in IBS-D by indirectly 
targeting 5-HT and thereby reduce the levels of 
proinflammatory mediators, such as IL-1, IL-2, 
IL-6, IL-8, IL-12, TNF-α and interferon (IFN)-γ, 
which are responsible for escalation of IBS symp-
toms and deterioration of the quality of life of 
patients with IBS [Ueda et al. 2008].
AST-120 and other mechanisms of 
enteroprotection
Farnesoid X receptor. Farnesoid X receptor 
(FXR), which is abundantly expressed in the liver, 
gut, kidneys, reproductive tissue, adrenal gland 
and pancreas, modulates transcription of genes 
involved in BA synthesis, transport and absorp-
tion. FXR acts as a BA sensor, which prevents 
intracellular BA overload and toxicity. Notably, 
activated FXR is involved in the negative feed-
back regulation of BA in the liver, predominantly 
by the modulation of fibroblast growth factor 
(FGF) 15/19. Accordingly, the BA-FXR-
FGF15/19 signalling pathway is an important 
mechanism which maintains the BA homeostasis 
in the gut. Gene knockout of any part of this path-
way results in an increased cholesterol 7-α 
hydroxylase (CYP7A1) mRNA expression and 
enhanced BA pool size, leading to exacerbated 
BA excretion. FXR-deficient mice experience 
aberration in BA and lipid homeostasis, with ele-
vated cholesterol levels in the liver, as well as 
serum [Sinal et al. 2000]. An impaired FXR-19, 
which normally binds to FGF–R4/Klotho-β on 
the basolateral surface of hepatocytes, blocks the 
cascade that represses the gene encoding CYP7A1 
causing diarrhoea [Camilleri and Di Lorenzo, 
2012]. Considering the capability of AST-120 to 
adsorb BAs in the intestinal lumen, we hypothe-
size that it could diminish gut peristalsis and 
therefore alleviate IBS-D symptoms through 
FXR-dependent pathways.
Of note, FXR activation involves an indirect influ-
ence on the modulation of epithelial permeability 
and proinflammatory mediators in the murine 
intestinal mucosa. In FXR–/– mice, an uncon-
trolled immune reaction occurred and the level of 
several proinflammatory mediators, including 
IFN-γ, TNF-α, IL-6, IL-18, suggesting an addi-
tional role of FXR in immunoregulation 
[Vavassori et al. 2009]. The study by Inagaki and 
colleagues provided strong evidence that FXR–/– 
mice experienced bacterial overgrowth, particu-
larly in mesenteric lymph nodes and developed 
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inflammation of the gut wall [Inagaki et al. 2006]. 
Consistently, elimination of intestinal BA by AST-
120 may upregulate FXR activation and restrain 
the accumulation of proinflammatory mediators 
by promoting the expression of genes involved in 
enteroprotection.
It needs to be underlined that a long-lasting elimi-
nation of BAs from the colon may result in a 
counter-regulatory increase in hepatic BA synthe-
sis, which will sustain the expression of FXR in 
the ileal epithelium [McGuckin et al. 2009]. 
Exacerbated secretion of BAs can result in dete-
rioration of symptoms in patients with IBS-D; 
however, it may be beneficial in IBS-C. This 
aspect still needs to be investigated further.
Intestinal bacteria. It is well known that the car-
bohydrate to nitrogen ratio is one of the crucial 
regulators of bacterial metabolism [Evenepoel 
et al. 2009]. Consistently, dietary restrictions 
implemented in patients with IBS can easily 
impair this balance and enlarge the generation of 
potentially toxic protein fermentation metabo-
lites, such as phenols. Higher endotoxin levels can 
exacerbate the levels of several cytokines and 
acute phase reactants, and lead to changes in the 
intestinal barrier, dysregulate its function and 
finally contribute to microscopic inflammation of 
enteric mucosa. AST-120, which has the ability to 
reduce the levels of microbial metabolites through 
adsorption onto a high-affinity surface may thus 
prevent the accumulation of toxins in the gut and 
preserve the intestine from any damage. Conse-
quently, AST-120 could decrease intestinal per-
meability and therefore reduce monocyte-derived 
cytokine level mediators in the gut.
Effectiveness and safety of AST-120 in IBS
Due to a very small number of clinical trials avail-
able, the influence of AST-120 cannot be unam-
biguously determined. A placebo-controlled, 
double-blind treatment study conducted by Tack 
and colleagues indicated at least 50% reduction 
in days with pain and bloating [Tack et al. 2011], 
rising from week 4 to week 8, in nonconstipating 
IBS after AST-120 treatment compared with the 
placebo group. Furthermore, amelioration of 
watery and loose stools was observed in patients 
with IBS-D. Noteworthy, no significant adverse 
effects were recorded, which justifies the potential 
of AST-120 in subsequent treatment of patients 
with nonconstipating IBS. Interestingly, the dose 
of 2 g was employed in the trial, which is similar 
to the regimen used in the treatment of CKD. 
Nevertheless, additional dose-ranging studies 
should be explored both in IBS-C and IBS-D.
Conclusion
Oral adsorbent AST-120 is believed to exert its 
action by removing uremic toxins, predominantly 
IS, within the intestine. Data show that AST-120 
can slow the deterioration in renal function and 
can prevent CVD progression; however, the pre-
cise mechanism by which AST-120 can influence 
IBS symptoms remains to be determined. Here 
we demonstrated several possibilities that may 
support the usefulness of AST-120 in IBS treat-
ment and expect that further investigations will 
provide novel insights into the complex mecha-
nism of its action. It needs to be underlined that 
the conclusions drawn in this paper rely predomi-
nantly on theoretical mechanisms and sequences 
of events that can occur after administration of 
AST-120 and thus its role in IBS still remains 
questionable.
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